MIA in the spotlight at ASCO virtual conference
30 May 2020
This year’s American Society of Clinical Oncology (ASCO) Annual Meeting has gone virtual, with researchers from MIA once again in the spotlight. Usually attended by over 40,000 professionals, ASCO’s Annual Meeting showcased global advances in research and treatment, all of which impact patient outcomes.
Headlining MIA’s contribution at ASCO 20 Virtual was Dr Ines Silva, a clinical fellow and post-doctoral researcher at MIA, who was awarded the prestigious Bradley Stuart Beller Endowed award for best abstract.
Dr Silva’s abstract related to an oral presentation delivered virtually at ASCO, assessing the impact of Ipilimumab-based immunotherapy in patients with metastatic melanoma whose disease had already proven resistant to anti-PD1 monotherapy.
The multicentre retrospective study involved 355 patients with Stage III or Stage IV melanoma whose cancer had progressed or recurred despite having anti-PD1 monotherapy. 46% of these patients were then treated with ipilimumab alone, with 54% receiving combination ipilimumab and anti-PD1 therapy.
In patients who received the follow up combination therapy, there was a higher response rate (32%) as well as longer progression free survival (25% at 12 months) and overall survival (58% at 12 months) compared to IPI alone. Importantly, IPI+anti-PD1 was not associated with more severe side effects than IPI monotherapy.
Dr Silva and the MIA team created clinical predictive models to help identify the patients who will benefit from these treatments.
‘It was an honour to deliver the oral presentation virtually at ASCO 20 Virtual,’ said Dr Silva. ‘Although we weren’t together physically, still being able to share insights and learnings globally was vitally important in ensuring we continue on our path to saving more lives from melanoma.’
Also awarded at ASCO 20 Virtual were Dr Adriana Hepner and Dr Lauren Brown who received merit awards for abstracts submitted. Overall, MIA researchers and clinicians contributed to 21 abstracts featured at ASCO.
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way in changing the treatment landscape for melanoma patients,’ MIA Co-Medical Director Professor Georgina Long said.
‘Our mission is zero deaths from melanoma, and by collaborating with our colleagues on the world stage we are confident we are on track to reach that goal within our lifetime,’ added MIA Co-Medical Director Professor Richard Scolyer.
Register to view Dr Silva's video and slides here: Dr Silva presentation
See the ASCO 20 Virtual Program here: ASCO 20 Virtual
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.
Using MIA's patient database, researchers have developed conditional survival estimates for Stage III melanoma patients to more accurately predict survival outcomes.
MIA is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.
Research achievements by MIA were celebrated at the annual Sydney Medical School recently.
In this Global Research Report we showcase advances in medical oncology, reveal unexpected pathology in acral and skin melanoma, and uncover biomarkers and new gene targets for melanoma.
Professor’s Long and Scolyer are well known in the academic community and beloved by their patients. But we wanted to get to know our new Conjoint Medical Directors a little more and hear their plans on making an impact on melanoma.
Wyong Rugby League Club Group has joined forces with Melanoma Institute Australia to help end melanoma for future generations.
Melanoma research has reached a milestone with the 10,000th patient giving their permission for their blood and tissue samples to be used in the world’s largest melanoma biospecimen bank.
MIA's researchers and clinicians are in Seattle, USA, today sharing their research findings at the prestigious Society of Surgical Oncology’s Annual Cancer Symposium.
Two of the world’s best minds in melanoma have taken over the academic and clinical leadership of Melanoma Institute Australia (MIA). Professor Georgina Long and Professor Richard Scolyer are the new Conjoint Medical Directors of MIA, and are shaping the future direction of melanoma research, treatment and education.